Redeye briefly comments on Initiator Pharma’s announcement that its Clinical Trial Application (CTA) for the planned phase IIa study in vulvodynia has been approved. We view this as an important milestone in the company’s strategic expansion into female sexual dysfunction, reducing its dependency on the ED program and strengthening its overall clinical outlook.
LÄS MER
